Inhibition of the mammalian target of rapamycin (mTOR) pathway extends life span in all
species studied to date, and in mice delays the onset of age-related diseases and …

The mammalian (mechanistic) target of rapamycin (mTOR) regulates critical immune
processes that remain incompletely defined. Interest in mTOR inhibitor drugs is heightened …

Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span
and ameliorates aging-related pathologies including declining immune function in model …

The TOR (target of rapamycin) pathway has been convincingly shown to promote aging in
various model organisms. In mice, inhibiting mTOR (mammalian TOR) by rapamycin …

Inhibition of the mTOR (mechanistic Target Of Rapamycin) signaling pathway robustly
extends the lifespan of model organisms including mice. The precise molecular mechanisms …

Inhibition of the mechanistic target of rapamycin (mTOR) pathway by rapamycin (RAPA), an
FDA-approved immunosuppressive drug used as a clinical therapy to prevent solid organ …

Inhibition of the mTOR (mechanistic target of rapamycin) signaling pathway by the FDA-
approved drug rapamycin promotes life span in numerous model organisms and delays age …

Aging of the world population and a concomitant increase in age‐related diseases and
disabilities mandates the search for strategies to increase healthspan, the length of time an …

Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA‐
approved drug rapamycin has been shown to promote lifespan and delay age‐related …

Aging is a major risk factor for a large number of disorders and functional impairments.
Therapeutic targeting of the aging process may therefore represent an innovative strategy in …